Surgery Partners Sweetens HealthSpan Deal to $25/Share After $28 Unsolicited Bid
SGRY has more than doubled off its 52-week low of $11.41.
Summary
Surgery Partners raised the HealthSpan Partners merger price to $25.00 a share in cash from $23.50 after receiving an unsolicited $28.00-a-share all-cash proposal from an unnamed third party on November 3, updated November 8. The amended deal adds a ticking fee of 10% per annum on the $25.00 consideration if stockholder approval is in hand but the merger hasn't closed by March 1, 2027, worth up to $1.61 a share and a maximum of $26.61 a share, or roughly $6.0 billion enterprise value. The board and Special Committee unanimously judged the $28.00 bid not a Superior Proposal, citing a materially longer and less certain closing timeline, higher regulatory risk and missing contractual protections. Bain Capital, at about 39% of shares, keeps its voting support agreement and will roll its stake rather than take cash. The stock at $23.18 sits just below the 52-week high of $23.37, so the market is already pricing a high probability of the HealthSpan deal; the $25.00 floor plus ticking fee narrows the gap to the $28.00 bid but the board has effectively closed the door on it. Closing is still expected in the first quarter of 2027, pending the stockholder vote and regulatory approvals.
At the time of this announcement, SGRY was trading at $23.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $11.41 to $23.37. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: BusinessWire.